Download MendeleyMolecular glue degraders of HuR suppress BRAF-mutant colorectal cancer.
Lu, X., Wang, X., Yang, Z., Wang, X., Wang, L., Xu, C., Lo, I.C., Geng, C., Wang, L., Pu, Y., Zhang, K., Zhu, Z., Ye, L., Huang, J., Wei, X., Bai, F., Zhu, Y., Qian, X., Dou, H., Su, H., Cang, Y.(2026) Nature
- PubMed: 42271059 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41586-026-10613-5
- Primary Citation Related Structures:
9W2F - PubMed Abstract:
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse 1-3 . Here, through rational chemical library design coupled with parallel proteomic screening, we identified dHuR as a molecular glue degrader of human antigen R (HuR), an RNA-binding protein that drives tumour growth, invasion and therapy resistance. dHuR binds to the CRBN ubiquitin ligase to create a unique benzofuran-tethered composite surface to recruit HuR as a neosubstrate by engaging its β-hairpin G-loop degron, as revealed by the cryo-electron microscopy structure of the ternary complex. dHuR abrogated BRAF expression by inducing its exon 18 skipping, and demonstrated superior suppression of BRAF-mutant CRC tumours including those gaining resistance to BRAF inhibitors. Finally, we performed kinome library CRISPR screening and revealed that inactivation of EGFR or MEK enhanced dHuR cytotoxicity, thus establishing a combinatorial strategy to treat patients with refractory BRAF-mutant CRC.
- School of Life Sciences and Technology, ShanghaiTech University, Shanghai, China.
Organizational Affiliation:
